What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
One morning early last July, Micha Bitsinnie arrived at work to an onslaught of messages from...
Authorities in France have placed more than a third of the country under a red heat...
An influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force...
